Key facts
- KAICO’s last known valuation is $18.4M (Apr 2025).
- It has raised $10.7M; the latest was Later Stage VC ($3.6M) in Apr 2025.
- Notable investors include Mizuho Capital, FFG Venture Business Partners, UntroD, DG Ventures, ITOCHU Technology Ventures — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for KAICO
- ·The full record, as it builds
Funding rounds
No funding rounds for KAICO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KAICO
Developer of silkworm-expressed protein technologies enabling safer and more sustainable biomanufacturing. The company leverages silkworm-based expression systems to produce complex proteins with high efficiency and reduced environmental impact, enabling pharmaceutical, biotechnology and industrial partners to access an alternative to conventional cell culture platforms.
- Sector
- Healthcare
- HQ
- Fukuoka, Japan
- Founded
- 2018
- Employees
- 50
- Website
- kaicoltd.jp/
- Ownership
- Privately Held (backing)
KAICO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KAICO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KAICO in its N-PORT filings yet. We sweep new filings monthly.